3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Lung Neoplasms
4
Glioma
4
Neoplasm Metastasis
3
Glioblastoma
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Esophageal Neoplasms
2
Carcinoma, Medullary
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
Carboplatin
10
pembrolizumab
9
Cisplatin
9
Paclitaxel
8
Radiotherapy, Intensity-Modulated
6
Magnetic Resonance Spectroscopy
6
Pemetrexed
5
Gemcitabine
5
fludarabine
4
Specimen Handling
4
Nivolumab
4
Cyclophosphamide
4
trebananib
3
osimertinib
3
liposomal doxorubicin
3
Radiotherapy
3
Midazolam
3
Interleukin-2
3
Fluorouracil
3
Docetaxel
3
DNA
3
volociximab
2
poly ICLC
2
lenvatinib
2
fludarabine phosphate
2
Sorafenib
2
Radiosurgery
2
Capecitabine
2
Biopsy
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma
×
vandetanib
×
Clear all
NCT00506051
2016-08-25
ZD6474(Vandetanib) + Alimta Combo Study
Sanofi
Phase 1
Completed
21 enrolled